EGFR Mutation Status and PD-L1 Expression in Patients ≤40 Years Old with NSCLC / 肿瘤防治研究
Mingming HU; Zichen LIU; Hongmei ZHANG; Baohua LU; Jie LI; Qunhui WANG; Fanbin HU; Haifeng LIN; Baolan LI; Tongmei ZHANG.
Cancer Research on Prevention and Treatment
; (12): 687-691, 2022.
Artículo
en Zh
| WPRIM | ID: wpr-986568
Objective To retrospectively analyze the clinical data of 47 young NSCLC patients mutation style of EGFR and PD-L1 expression in tumor cells, to understand their clinicopathological and molecular characteristics. Methods We enrolled 47 young (≤40 years old) patients confirmed as NSCLC who underwent surgical resection, and 94 old patients (≥60 years old) were matched as 12 by R language. EGFR mutation status was detected by ARMS-PCR, and the expression of PD-L1 was detected by immunohistochemistry. Results The median age of 47 young patients with NSCLC was 37 years old. The disease was more common in women and the majority type was adenocarcinoma. In youth group, the 19del and 20ins were more frequent, but the exon 21 L858R point mutation proportion was higher in elder group. The expression of PD-L1 was significantly increased in the solid predominant histological subtype. The PD-L1 expression in 19del patients was higher than that in the patients with L858R mutation in youth group. Conclusion The majority of young NSCLC patients are female, nonsmokers and suffered from adenocarcinoma cancer. The proportion of EGFR alteration in 19del and 20ins in youth group is higher than that in elder group. The positive rate of PD-L1 expression in solid predominant histological subtype is higher than that with other subtypes. The expression of PD-L1 in young patients with EGFR 19del is higher than that with L858R.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados